LUIZ GUILHERME CERNAGLIA AURELIANO DE LIMA
Índice h a partir de 2011
3
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
9 resultados
Resultados de Busca
Agora exibindo 1 - 9 de 9
conferenceObject Characterization of EGFR Activating Mutations in Brazilian Patients with Pulmonary Adenocarcinoma(2015) YEN, Cheng T.; BITTON, Rafael C.; LIMA, Luiz G. C. A. De; AMADIO, Alex V.; TAKAHASHI, Tiago K.; MARINI, Andrea M.; TAKAGAKI, Tereza Y.; TERRA, Ricardo M.; MELLO, Evandro S.; CASTRO JR., Gilberto De- Tumor Reduction with Pazopanib in a Patient with Recurrent Lumbar Chordoma(2018) RIBEIRO, Mauricio Fernando Silva Almeida; SOUSA, Micelange Carvalho de; HANNA, Samir Abdallah; MALDAUN, Marcos Vinicius Calfat; KURIMORI, Ceci Obara; LIMA, Luiz Guilherme Cernaglia Aureliano de; MATTEDI, Romulo Loss; MUNHOZ, Rodrigo RamellaIntroduction. Chordomas are rare malignancies of bone origin that occur in the axial skeleton, typically the skull base and lumbar/sacral regions. Although often classified as low-grade neoplasms, its locally infiltrative behavior may result in significant morbidity and mortality. Optimal surgical resection may be curative, but up to 50% of the cases relapse within 5 years, and currently there are no systemic treatments approved in this setting. A large proportion of these tumors express stem-cell factor receptor (c-KIT) and platelet-derived growth factor receptors (PDGFRs), providing a rationale for the use of tyrosine-kinase inhibitors (TKIs). Case report. A 27-year-old male presented with recurrent chordoma of the lumbar spine 4 years after initial diagnosis. Salvage therapies in the interval included repeat resections and radiation therapy. He ultimately developed multifocal recurrence not amenable to complete excision or reirradiation. A comprehensive genomic profiling assay was performed and revealed nondrugable alterations. Decision was made to proceed with systemic treatment with pazopanib 800 mg/day, resulting in tumor reduction (-23.1% reduction in size) and prolonged disease control. Conclusion. For this patient with a multiple recurrent chordoma and limited treatment options, pazopanib resulted in sustained clinical benefit following initial tumor reduction.
- Complete response to alectinib following crizotinib in an ALK-positive tumor with CNS involvement(2021) XAVIER, Camila B.; CANEDO, Felipe S. N. A.; LIMA, Fabiola A. S.; MELO, Raissa R.; LIMA, Luiz Guilherme C. A.; MARIN, Jose Flavio G.; SOUZA, Ciro E.; FEHER, OlavoInflammatory myofibroblastic tumor (IMT) is a rare entity that affects mostly children and young adults. The lungs are the most frequent primary site. When feasible, surgical resection is the standard of care and it is associated with long-term survival benefit. Metastatic disease is rare, and central nervous system involvement is very infrequent. There is paucity of data regarding systemic treatment of recurrent or metastatic disease but most IMTs present with ALK rearrangements, becoming potential targets to ALK inhibition. Diagnosis of ALK rearrangements by FISH or RT-PCR is standard and discordant results from immunohistochemistry are rare. Crizotinib is considered the standard therapy in ALK-positive cases. Data supporting the use of other ALK inhibitors are scant and derived only from case reports. We report a case of a patient harboring an ALK-positive by IHC, FISH-negative IMT, that initially responded well to crizotinib but progressed in the CNS, presenting a complete CNS response with second-generation ALK inhibitor alectinib.
conferenceObject Nodal Upstaging Comparison of Open, Video-Assisted Thoracoscopic, and Robotic Lung Resections Form Non-Small Cell Lung Cancer(2021) TERRA, R.; VEGA, A. Dela; LAURICELLA, L.; ROCHA JR., E.; LIMA, L.; CREMONESE, M.; PEGO-FERNANDES, P.conferenceObject Learning Curve in Robotic-Assisted Thoracoscopic Pulmonary Resection: Experience of a Brazilian Surgeon(2021) TERRA, R.; SOARES, M.; LIMA, L.; LAURICELLA, L.; ARAUJO, P. H. De; CAMPOS, J. R. De; PEGO-FERNANDES, P.- Neoadjuvant stereotactic ablative radiotherapy (SABR) for soft tissue sarcomas of the extremities(2021) LEITE, Elton Trigo Teixeira; MUNHOZ, Rodrigo Ramella; CAMARGO, Veridiana Pires de; LIMA, Luiz Guilherme Cernaglia Aureliano de; REBOLLEDO, Daniel Cesar Seguel; MAISTRO, Carlos Eduardo Bravin; BUSNARDO, Fabio de Freitas; FERREIRA, Fabio de Oliveira; SALVAJOLI, Joao Victor; CARVALHO, Heloisa de AndradeBackground: Soft tissue sarcomas (STS) comprise a diverse group of mesenchymal malignancies that require multidisciplinary care. Although surgery remains the primary form of treatment for those with localized disease, radiation therapy (RT) is often incorporated either in the neo-or adjuvant setting. Given the development of modern RT techniques and alternative dosing schedules, stereotactic ablative radiotherapy (SABR) has emerged as a promising technique. However, the current role of SABR in the treatment of STS of the extremities remains uncertain. Methods and Materials: This was a single-center, prospective, single-arm phase II trial. Patients with localized STS who were candidates for limb-preservation surgery were included. Experimental treatment consisted of SABR with 40 Gy in 5 fractions, administered on alternate days, followed by surgery after a minimum interval of 4 weeks. The primary outcome was the rate of wound complication. Secondary outcomes included 2-year local control (LC), metastasis-free survival (MFS), cancer-specific survival (CSS), and overall survival (OS) rates (and other toxicities). Results: Twenty-five patients were enrolled between October 2015 and November 2019 and completed the treatment protocol. The median rate of histopathologic regression was 65% (range 0-100) and 20.8% of tumors presented pathologic complete response (pCR). Wound complications were observed in 7/25 patients (28%). Three patients underwent disarticulation by vascular occlusion after plastic reconstruction and one patient was amputated by grade 3 limb dysfunction. After a median follow up of 20.7 months, the 2-year estimated risk of local recurrence, distant metastasis and cause-specific death were 0%, 44.7% and 10.6% respectively. Conclusions: Neoadjuvant SABR appears to improve the pCR for patients with eSTS, with acceptable rate of wound complications. Nevertheless, this benefit should be weighed against the risk of late of vascular toxicity with SABR regimen since, even in a short median follow-up, a higher rate of amputation than expected was observed. A larger sample size with longer follow-up is necessary to conclude the overall safety of this strategy.
conferenceObject Association of stromal cell gene expression with response to neoadjuvant chemotherapy in locally advanced breast cancer(2014) VIEIRA, Rene Aloisio da Costa; MATTHES, Angelo Gustavo Zucca; KATAYAMA, Maria Lucia Hirata; ANDRADE, Victor Piana; ROELA, Rosimeire Aparecida; LIMA, Luiz Guilherme C. A.; MAISTRO, Simone; BRENTANI, Maria Mitzi; FOLGUEIRA, Maria A. A. KoikeconferenceObject Impact of histopathological revision and molecular pathology in the diagnosis of sarcomas in a reference center in Brazil.(2022) LOPES, Carlos Diego Holanda; QUEIROZ, Marcello Moro; SAMPAIO, Luana Alencar Fernandes; PERINA, Andre; AKAISHI, Eduardo Hiroshi; TEIXEIRA, Frederico Ribeiro; FERREIRA, Fabio Oliveira; HANNA, Samir Abdallah; SILVA, Joao Luis da; LIMA, Luiz Guilherme C. A. De; OLIVEIRA, Claudia Regina G. C. M. De; MUNHOZ, Rodrigo RamellaconferenceObject Validating ECOG Performance Status as a Prognostic Factor in Brazilian Patients with Pulmonary Adenocarcinoma(2015) BITTON, Rafael C.; LIMA, Luiz G. C. A. De; ROITBERG, Felipe S. R.; MESQUITA, Cristiane; MARTINS, Renata E.; YEN, Cheng T.; TERRA, Ricardo M.; MELLO, Evandro S.; CASTRO JR., Gilberto De